collection
MENU ▼
Read by QxMD icon Read
search

Inpatient Psychopharmacology Lit Search

shared collection
168 papers 100 to 500 followers
By Edwin Kim Resident Physician, Aspiring Addiction Psychiatrist
https://www.readbyqxmd.com/read/15784664/the-serotonin-syndrome
#1
REVIEW
Edward W Boyer, Michael Shannon
No abstract text is available yet for this article.
March 17, 2005: New England Journal of Medicine
https://www.readbyqxmd.com/read/22534658/a-retrospective-analysis-of-two-randomized-trials-of-bupropion-for-methamphetamine-dependence-suggested-guidelines-for-treatment-discontinuation-augmentation
#2
RANDOMIZED CONTROLLED TRIAL
Matthew Brensilver, Keith G Heinzerling, Aimee-Noelle Swanson, Steven J Shoptaw
BACKGROUND: Two clinical trials have shown efficacy for bupropion in treating methamphetamine (MA) dependence among those with moderate baseline MA use. However, treatment response is highly variable and it is unclear what duration of treatment is necessary to determine if maintaining the treatment course is indicated or if discontinuation or augmentation is appropriate. The present study assessed the relationship among early bupropion treatment response for moderate MA users and end-of-treatment (EOT) abstinence...
September 1, 2012: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28448701/valproate-intoxication-in-a-patient-with-blood-valproate-levels-within-therapeutic-range
#3
Johanna E M P Smits, Eveline Wallenburg, Arno van Spanje, Matthijs van Luin, Radboud M Marijnissen
No abstract text is available yet for this article.
April 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28112047/venous-thromboembolism-during-treatment-with-antipsychotics-results-of-a-drug-surveillance-program
#4
Martin Letmaier, Renate Grohmann, Christiana Kren, Sermin Toto, Stefan Bleich, Rolf Engel, Thomas Gary, Konstantinos Papageorgiou, Anastasios Konstantinidis, Anna Katharina Holl, Annamaria Painold, Siegfried Kasper
OBJECTIVES: Venous thromboembolism (VTE) can be a life-threatening medical condition that may lead to leg swelling, respiratory distress and death. METHODS: The AMSP (Arzneimittelsicherheit in der Psychiatrie) is a continuous multicenter drug surveillance program that assesses severe adverse drug reactions during treatment of psychiatric inpatients. We report on a total of 264,422 inpatients who were treated with antipsychotics (APs) and monitored from 1993 to 2011 in 99 psychiatric hospitals...
January 23, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/19558259/worsening-psychosis-induced-by-varenicline-in-a-hospitalized-psychiatric-patient
#5
Bethany A DiPaula, Michele D Thomas
Varenicline is a novel treatment for smoking cessation; however, the agent has not been well studied in a population with severe mental illness. Varenicline can reportedly cause neuropsychiatric adverse effects, some resulting in hospitalizations and/or suicides. We describe a case of clinician-observed, worsening psychotic symptoms in a patient with chronic mental illness who was receiving varenicline. A 45-year-old woman with bipolar disorder, mixed type with psychotic features, was admitted to a psychiatric hospital due to acute decompensation after she discontinued her drug therapy...
July 2009: Pharmacotherapy
https://www.readbyqxmd.com/read/18984856/varenicline-associated-acute-renal-failure
#6
Matthew L Bird, Kimi S Vesta
OBJECTIVE: To report an association between acute renal failure and varenicline. CASE SUMMARY: A 53-year-old white male with preexisting moderate renal insufficiency was admitted to the hospital for acute renal failure following a change in serum creatinine from 4 mg/dL at baseline to 10.6 mg/dL upon admission. One week prior to admission, the patient started taking varenicline (dose undetermined) for smoking cessation and had been stable on all other medications for 2 months prior to admission...
December 2008: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/26921057/add-on-effects-of-a-low-dose-aripiprazole-in-resolving-hyperprolactinemia-induced-by-risperidone-or-paliperidone
#7
Ying Qiao, Fuzhong Yang, Chunbo Li, Qian Guo, Hui Wen, Suoyu Zhu, Qiong Ouyang, Weidi Shen, Jianhua Sheng
This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period...
March 30, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/27203278/lurasidone-the-2016-update-on-the-pharmacology-efficacy-and-safety-profile
#8
REVIEW
Rafał R Jaeschke, Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Krzysztof Styczeń, Wojciech Datka
The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of lurasidone. Lurasidone is an atypical antipsychotic, approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar depression. Lurasidone exhibits both an antipsychotic and antidepressant action. Based on its pharmacodynamics profile, it is believed that the drug's clinical action is mediated mainly through the D2, 5-HT2A and 5-HT7 receptors inhibition. In patients with schizophrenia the recommended dose range is 40-80mg/day...
August 2016: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/26455671/recommendations-for-the-monitoring-of-serum-concentrations-of-antipsychotic-drugs-in-the-treatment-of-schizophrenia
#9
Leonardo V Lopez, John M Kane
No abstract text is available yet for this article.
September 2015: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/26816428/comparative-study-of-sexual-dysfunction-and-serum-prolactin-level-associated-with-olanzapine-risperidone-and-clozapine-in-patients-with-remitted-schizophrenia
#10
S V Sathish Kumar, Vinod Kumar Sinha
BACKGROUND: Sexual dysfunctions have been a major side effect of the second generation anti-psychotic drugs which often affects treatment compliance in patients with schizophrenia. There is no/few systematic review or research addressing sexual dysfunction and their effect on serum prolactin level among different atypical antipsychotics in India. AIMS: To determine and compare the frequency of sexual dysfunction associated with olanzapine, risperidone, and clozapine and their effect on serum prolactin level in remitted patients with schizophrenia...
October 2015: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/26674884/asenapine-for-bipolar-disorder
#11
REVIEW
Thomas Scheidemantel, Irina Korobkova, Soham Rej, Martha Sajatovic
Asenapine (Saphris(®)) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the treatment of schizophrenia in adults, as well as the treatment of acute manic or mixed episodes of bipolar I in both adult and pediatric populations. Asenapine is a tetracyclic drug with antidopaminergic and antiserotonergic activity with a unique sublingual route of administration. In this review, we examine and summarize the available literature on the safety, efficacy, and tolerability of asenapine in the treatment of bipolar disorder (BD)...
2015: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/26316822/the-effectiveness-and-limitations-of-regulatory-warnings-for-the-safe-prescribing-of-citalopram
#12
Kevin J Friesen, Shawn C Bugden
BACKGROUND: Citalopram is the most commonly prescribed antidepressant in Canada. Concerns have been raised about its cardiac safety, and a dose-dependent prolongation of the QT interval has been documented. Drug interactions involving concomitant use of other medications that prolong the QT interval or increase citalopram levels by interfering with its metabolism increase the cardiac risk. Regulatory bodies (Health Canada and the US Food and Drug Administration) issued warnings and required labeling changes in 2011/2012, suggesting maximum citalopram doses (<40 mg for those <65 years; <20 mg for those ≥65 years) and avoiding drug interactions that increase cardiac risk...
2015: Drug, Healthcare and Patient Safety
https://www.readbyqxmd.com/read/26541815/comparative-effectiveness-of-clozapine-and-standard-antipsychotic-treatment-in-adults-with-schizophrenia
#13
COMPARATIVE STUDY
T Scott Stroup, Tobias Gerhard, Stephen Crystal, Cecilia Huang, Mark Olfson
OBJECTIVE: The authors compared the effectiveness of initiating treatment with either clozapine or a standard antipsychotic among adults with evidence of treatment-resistant schizophrenia in routine clinical practice. METHOD: U.S. national Medicaid data from 2001 to 2009 were used to examine treatment outcomes in a cohort of patients with schizophrenia and evidence of treatment resistance that initiated clozapine (N=3,123) and in a propensity score-matched cohort that initiated a standard antipsychotic (N=3,123)...
February 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/26417330/clinical-pharmacology-of-atypical-antipsychotics-an-update
#14
REVIEW
M C Mauri, S Paletta, M Maffini, A Colasanti, F Dragogna, C Di Pace, A C Altamura
This review will concentrate on the clinical pharmacology, in particular pharmacodynamic data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, que¬tiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and cariprazine. A summary of their acute pharmacokinetics properties are also reported. Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine. Similar to ziprasidone and aripiprazole, these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second-generation antipsychotics such as olanzapine or clozapine...
2014: EXCLI journal
https://www.readbyqxmd.com/read/25653829/aripiprazole-versus-quetiapine-in-treatment-resistant-obsessive-compulsive-disorder-a-double-blind-clinical-trial
#15
Saeed Shoja Shafti, Hamid Kaviani
INTRODUCTION: Around 40-60% of the patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Goal of this study was to compare the efficiency and safety of aripiprazole versus quetiapine, in patients with OCD, who did not respond effectively to fluvoxamine. METHOD: A total of 44 female inpatients with OCD, who did not respond successfully to fluvoxamine at maximum dose (300 mg/day) and duration (12 weeks), were assigned randomly, in a double-blind trial, to receive aripiprazole (n = 22) or quetiapine (n = 22), in addition to their SRI, for 12 weeks...
February 2015: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/26403538/clinical-benefits-and-impact-of-early-use-of-long-acting-injectable-antipsychotics-for-schizophrenia
#16
REVIEW
Georgia L Stevens, Gail Dawson, Jacqueline Zummo
AIM: Results from clinical trials support the use of oral antipsychotics for treatment of early or first-episode psychosis in patients with schizophrenia. This paper will review literature on the advantages of early initiation of treatment for schizophrenia and the clinical benefits of early use of long-acting injectable antipsychotics (LAIs). METHOD: A comprehensive literature review was conducted to identify published literature on the use of LAIs early in the treatment of schizophrenia...
October 2016: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/26441156/reproductive-safety-of-second-generation-antipsychotics-current-data-from-the-massachusetts-general-hospital-national-pregnancy-registry-for-atypical-antipsychotics
#17
Lee S Cohen, Adele C Viguera, Kathryn A McInerney, Marlene P Freeman, Alexandra Z Sosinsky, Danna Moustafa, Samantha P Marfurt, Molly A Kwiatkowski, Shannon K Murphy, Adriann M Farrell, David Chitayat, Sonia Hernández-Díaz
OBJECTIVE: Second-generation antipsychotics are used to treat a spectrum of psychiatric illnesses in reproductive-age women. The National Pregnancy Registry for Atypical Antipsychotics was established to determine the risk of major malformations among infants exposed to second-generation antipsychotics during pregnancy relative to a comparison group of unexposed infants of mothers with histories of psychiatric morbidity. METHOD: Women were prospectively followed during pregnancy and the postpartum period; obstetric, labor, delivery, and pediatric medical records were obtained...
March 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/26061612/paliperidone-palmitate-long-acting-injectable-given-intramuscularly-in-the-deltoid-versus-the-gluteal-muscle-are-they-therapeutically-equivalent
#18
REVIEW
John Yin, Abby C Collier, Alasdair M Barr, William G Honer, Ric M Procyshyn
Paliperidone palmitate long-acting injectable is a second-generation antipsychotic indicated for the treatment of schizophrenia. According to the product monograph, the monthly maintenance dose of paliperidone palmitate can be given in either the deltoid or gluteal muscle. Unfortunately, many clinicians may misinterpret these directions to mean that these intramuscular sites are interchangeable, and thus therapeutically equivalent. Currently, the literature on this topic is sparse, but the published pharmacokinetic studies and Food and Drug Administration submission data on paliperidone palmitate show discrepancies in the elimination half-life, peak plasma concentration, and absorption rate that are dependent on the site of injection...
August 2015: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/21057238/effectiveness-of-risperidone-for-the-treatment-of-nightmares-in-veterans-with-posttraumatic-stress-disorder
#19
LETTER
Nina Khachiyants, Rizwan Ali, Csaba P Kovesdy, Jonna G Detweiler, Kye Y Kim, Mark B Detweiler
No abstract text is available yet for this article.
December 2010: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/26378122/antipsychotic-induced-metabolic-effects-in-the-female-rat-direct-comparison-between-long-acting-injections-of-risperidone-and-olanzapine
#20
Kari M Ersland, Silje Skrede, Therese H Røst, Rolf K Berge, Vidar M Steen
Several antipsychotics have well-known adverse metabolic effects. Studies uncovering molecular mechanisms of such drugs in patients are challenging due to high dropout rates, previous use of antipsychotics and restricted availability of biological samples. Rat experiments, where previously unexposed animals are treated with antipsychotics, allow for direct comparison of different drugs, but have been hampered by the short half-life of antipsychotics in rodents. The use of long-acting formulations of antipsychotics could significantly increase the value of rodent models in the molecular characterization of therapeutic and adverse effects of these agents...
December 2015: Journal of Psychopharmacology
label_collection
label_collection
2536
1
2
2015-09-20 22:34:18
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"